Cronos Group(US:CRON)2026-02-26 12:38Financial Performance - Consolidated net revenue for 2025 was $146.6 million, a 25% increase from $117.6 million in 2024, primarily driven by higher cannabis flower sales in Israel and other countries [358]. - Gross profit for 2025 reached $62.8 million, representing a 149% increase from $25.2 million in 2024, with a gross margin of 43% compared to 21% in the previous year [359]. - The company reported a net loss attributable to Cronos Group of $9.4 million in 2025, compared to a net income of $41.1 million in 2024 [358]. - The net loss for the year ended December 31, 2025, was $2.9 million, compared to a net income of $40.0 million in 2024 [393]. - For 2025, net revenue was $146.6 million, a 25% increase from $117.6 million in 2024, with constant currency revenue at $145.4 million, reflecting a 24% increase [402]. - Gross profit for 2025 was $62.8 million, a 149% increase from $25.2 million in 2024, with constant currency gross profit at $61.8 million, representing a 145% increase [404]. - Adjusted Gross Profit for the year ended December 31, 2025, was $63.3 million, representing an increase of $32.8 million from $30.5 million in 2024 [400]. - The company reported a foreign currency transaction loss of $28.6 million for the year ended December 31, 2025 [393]. Cost Management - The cost of sales decreased by $8.5 million to $83.2 million in 2025, attributed to lower inventory step-up costs and production efficiencies [361]. - Total operating expenses decreased by 21% to $80.2 million in 2025 from $101.7 million in 2024, primarily due to lower general and administrative expenses [364]. - General and administrative expenses decreased by 10% to $42.0 million in 2025, attributed to lower salaries and benefits [367]. - Sales and marketing expenses for 2025 were $21.8 million, a slight increase of 1% from 2024 [365]. - Research and development expenses rose to $4.4 million in 2025, reflecting a 5% increase from 2024 [366]. Strategic Initiatives - Cronos entered into a definitive agreement to acquire CanAdelaar B.V., a licensed cannabis producer in the Netherlands, subject to regulatory approvals [338]. - The company completed the expansion of Cronos GrowCo's facility, with sales from the expansion commencing in Fall 2025, aiming to fuel growth in both domestic and international markets [339]. - New product launches in 2025 included Spinach® gummies and PEACE NATURALS® strain-specific oils, enhancing the brand portfolio and market presence [348][350]. - The LIT™ brand expanded into the German and UK medical markets, capitalizing on local market trends to build brand loyalty [352]. Cash Flow and Investments - Cash and cash equivalents and short-term investments decreased by 4% to $828.2 million as of December 31, 2025, from $858.8 million in 2024 [408]. - The company generated $25.9 million from operating activities in 2025, an increase of $7.0 million compared to $18.8 million in 2024 [411]. - Cash used in investing activities was $76.6 million in 2025, a significant change of $251.7 million from cash provided in 2024 [412]. - Cash used in financing activities increased to $19.9 million in 2025, compared to $1.2 million in 2024, primarily due to share repurchases and dividends [413]. Foreign Currency Impact - Foreign currency transaction losses amounted to $28.6 million in 2025, a significant change of $86.4 million from 2024 [382]. - For the years ended December 31, 2025 and December 31, 2024, the company reported foreign currency gains of $48.7 million and losses of $(86.3) million, respectively [443]. - A 10% change in the exchange rates for the Canadian dollar would affect the carrying amount of net assets by approximately $40.5 million and $40.1 million as of December 31, 2025 and December 31, 2024, respectively [443]. - The company has not historically engaged in hedging transactions to mitigate foreign exchange risks and does not currently plan to do so [443]. - Appreciating foreign currencies relative to the U.S. dollar adversely impacts operating income and net earnings, while depreciating foreign currencies have a positive impact [442]. Adjusted EBITDA and Losses - For the year ended December 31, 2025, the company reported an Adjusted EBITDA of $10.1 million, an improvement of $45.1 million from the previous year [397]. - Adjusted EBITDA improved to $8.6 million in 2025, a $43.5 million increase from a negative $34.9 million in 2024 [407]. - The company incurred restructuring costs of $2.0 million for the year ended December 31, 2025, related to employee severance and IT infrastructure [396]. - Impairment losses on long-lived assets for the year ended December 31, 2025, amounted to $3.4 million [394].